Molecular pathways regulating macrophage polarization: Implications for atherosclerosis

Current Atherosclerosis Reports

Volumn 14, Issue 3, 2012, Pages 254-263

  Hoeksema, Marten A ^a   Stöger, J Lauran ^a   De Winther, Menno P J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular disease; Coronary artery disease; Cytokines; Epigenetics; Foam cells; Gene regulation; Heterogeneity; Human pathology; Inflammation; Innate immunity; Macrophages; Microenvironment; Mouse models; Polarization; Transcription factors

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT PROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL SUBPOPULATION; CELLULAR PARAMETERS; EPIGENETICS; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGE POLARIZATION; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT;

ANIMALS; ATHEROSCLEROSIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES;

EID: 84861235692     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0240-5     Document Type: Article

References (100)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747-57. (Pubitemid 43767064)
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American heart association. Circulation. 2010;121(7):e46-e215.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
5. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225-8. (Pubitemid 41615541)
6. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290(7):891-7. (Pubitemid 37430460)
7. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-41.
8. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52(3):722-32. (Pubitemid 40365093)
9. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronaryartery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407-15. (Pubitemid 37542989)
10. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89(9):763-71. (Pubitemid 34633846)
11. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-40.
12. Ridker PM. The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP? Arterioscler Thromb Vasc Biol. 2008;28(7):1222-4.
13. Rubin J, Chang HJ, Nasir K, et al. Association between highsensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population. Circ Cardiovasc Imaging. 2011;4(3):201-9.
14. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation. 1998;98(9):839-44. (Pubitemid 28397432)
15. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-8. (Pubitemid 40075677)
16. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA. 1998;279(20):1615-22. (Pubitemid 28248586)
17. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med. 2008;359(21):2195-207.
18. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7 Suppl 1:332-9. This prospective trial examined the impact of low-dose metothraxate on cardiovascular endpoints.
19. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605. This prospective trial studied the impact of canakinumab on cardiovascular endpoints.
20. Smith JD, Trogan E, Ginsberg M, et al. Decreased atherosclerosis in mice deficient in bothmacrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995;92(18):8264-8.
21. Rajavashisth T, Qiao JH, Tripathi S, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptordeficient mice. J Clin Invest. 1998;101(12):2702-10. (Pubitemid 28294579)
22. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117(1):185-94. (Pubitemid 46048465)
23. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515-81.
24. van Vlijmen BJ, Gerritsen G, Franken AL, et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-leiden transgenic mice. Circ Res. 2001;88(8):780-6. (Pubitemid 32429973)
25. Ball RY, Stowers EC, Burton JH, et al. Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis. 1995;114(1):45-54.
26. Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res. 2009;50(Suppl): S382-7.
27. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998;97(24):2433-44. (Pubitemid 28278188)
28. Johnson JL, Sala-Newby GB, Ismail Y, et al. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol. 2008;28(9):1647-53.
29. Pedersen SF, Graebe M, Fisker Hag AM, et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31(5):423-9.
30. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(7):1009-16.
31. van der Wal AC, Das PK, Tigges AJ, Becker AE. Macrophage differentiation in atherosclerosis. An in situ immunohistochemical analysis in humans. Am J Pathol. 1992;141(1):161-8.
32. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23-35. (Pubitemid 37328697)
33. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-61. (Pubitemid 351599757)
34. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-69.
35. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723-37.
36. Loke P, Gallagher I, Nair MG, et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol. 2007;179(6):3926-36.
37. Reese TA, Liang HE, Tager AM, et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature. 2007;447(7140):92-6. (Pubitemid 46685837)
38. HesseM, ModolellM, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of Larginine metabolism. J Immunol. 2001;167(11):6533-44. (Pubitemid 33081589)
39. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771-7.
40. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593-604.
41. Fleetwood AJ, Dinh H, Cook AD, et al. GM-CSF- and MCSF- dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol. 2009;86(2):411-21.
42. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocytemacrophage colony-stimulating factor (CSF) and macrophage CSFdependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol. 2007;178(8):5245-52. (Pubitemid 46595309)
43. Gleissner CA, Shaked I, Little KM, Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol. 2010;184(9):4810-8.
44. Kadl A, Meher AK, Sharma PR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res. 2010;107(6):737-46.
45. Lee S, Huen S, Nishio H, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2):317-26. This article shows macrophage plasticity in a transient in vivo model of inflammation.
46. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-84. (Pubitemid 46048464)
47. Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A. 2011;108(37):15324-9.
48. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11 (11):738-49.
49. Stoger JL, Goossens P, deWinther MP. Macrophage heterogeneity: relevance and functional implications in atherosclerosis. Curr Vasc Pharmacol. 2010;8(2):233-48.
50. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009;29(10):1419-23.
51. Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. 2011;106(5):763-71.
52. Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010;5(1): e8852.
53. Feig JE, Parathath S, Rong JX, et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation. 2011;123(9):989-98. This article very elegantly shows that induction of atherosclerosis regression by reversal of hyperlipidemia leads to a shift from CAM macrophages to an AAM phenotype in atherosclerotic lesions.
54. Shalhoub J, Cross A, Allin D, et al. Cytokine profiling in culture reveals a predominance of M1 macrophage polarisation in symptomatic carotid plaques. Presented on the BSCR Spring Meeting. 2010;96(17):e23-e23.
55. Hirata Y, Tabata M, Kurobe H, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol. 2011;58(3):248-55.
56. Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond). 2011;8:9.
57. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011;89(4):557-63.
58. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11(11):750-61.
59. Soler C, Felipe A, Garcia-Manteiga J, et al. Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways. Biochem J. 2003;375(Pt 3):777-83. (Pubitemid 37433528)
60. Agrawal S, Febbraio M, Podrez E, et al. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation. 2007;115(23):2939-47. (Pubitemid 46912097)
61. Lim WS, Timmins JM, Seimon TA, et al. Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation. 2008;117(7):940-51. (Pubitemid 351272592)
62. Ishii M, Wen H, Corsa CA, et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood. 2009;114 (15):3244-54.
63. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med. 2001;7(12):1291-7. (Pubitemid 34007932)
64. Brand K, Page S, Rogler G, et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97(7):1715-22. (Pubitemid 26105480)
65. Fong CH, Bebien M, Didierlaurent A, et al. An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J Exp Med. 2008;205(6):1269-76. (Pubitemid 351831484)
66. Kanters E, Pasparakis M, Gijbels MJ, et al. Inhibition of NFkappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;112 (8):1176-85. (Pubitemid 38056294)
67. Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009;106(35):14978-83.
68. Kanters E, Gijbels MJ, van der Made I, et al. Hematopoietic NFkappaB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood. 2004;103(3):934-40. (Pubitemid 38129553)
69. Satoh T, Takeuchi O, Vandenbon A, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010;11(10):936-44.
70. Takaoka A, Yanai H, Kondo S, et al. Integral role of IRF-5 in the gene induction programme activated by toll-like receptors. Nature. 2005;434(7030):243-9. (Pubitemid 40388058)
71. Krausgruber T, Blazek K, Smallie T, et al. IRF5 Promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12(3):231-8.
72. Liu J, Cao S, Herman LM, Ma X. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med. 2003;198(8):1265-76. (Pubitemid 37323391)
73. Yoshida K, Yamamoto K, Kohno T, et al. Active repression of IFN regulatory factor-1-mediated transactivation by IFN regulatory factor-4. Int Immunol. 2005;17(11):1463-71. (Pubitemid 41631322)
74. Guo M, Mao X, Ji Q, et al. Inhibition of IFN regulatory factor-1 down-regulate Th1 cell function in patients with acute coronary syndrome. J Clin Immunol. 2010;30(2):241-52.
75. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447(7148):1116-20. (Pubitemid 47014427)
76. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6 (2):137-43. (Pubitemid 47189091)
77. Pourcet B, Feig JE, Vengrenyuk Y, et al. LXRalpha regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ Res. 2011;109(5):492-501.
78. Babaev VR, Yancey PG, Ryzhov SV, et al. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25(8):1647-53. (Pubitemid 41098935)
79. Li G, Biju KC, Xu X, et al. Macrophage LXRalpha gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-/-) mice. Gene Ther. 2011;18(8):835-41.
80. Qu A, Shah YM, Manna SK, Gonzalez FJ. Disruption of endothelial peroxisome proliferator-activated receptor gamma accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2012;32(1):65-73.
81. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ Res. 2011;108 (8):985-95. This group (also reference 76) was the first to demonstrate CAM and AAM macrophages in human atherosclerosis and identified functional differences in macrophage lipid handling.
82. Buxadé M, Lunazzi G, Minguillón J, et al. Gene expression induced by Toll-like receptors in macrophages requires the transcription factor NFAT5. JEM. 2012.
83. Halterman JA, Kwon HM, Zargham R, et al. Nuclear factor of activated T cells 5 regulates vascular smooth muscle cell phenotypic modulation. Arterioscler Thromb Vasc Biol. 2011;31 (10):2287-96.
84. Whyte CS, Bishop ET, Ruckerl D, et al. Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol. 2011;90(5):845-54.
85. Ortiz-Munoz G, Martin-Ventura JL, Hernandez-Vargas P, et al. Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(4):525-31.
86. Liu Y, Stewart KN, Bishop E, et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol. 2008;180(9):6270-8.
87. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol. 2004;172(1):567-76. (Pubitemid 38020514)
88. Khan JA, Cao M, Kang BY, et al. AAV/hSTAT3-gene delivery lowers aortic inflammatory cell infiltration in LDLR KO mice on high cholesterol. Atherosclerosis. 2010;213(1):59-66.
89. Ruffell D, Mourkioti F, Gambardella A, et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc Natl Acad Sci U S A. 2009;106(41):17475-80.
90. van Tits LJ, Stienstra R, van Lent PL, et al. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for kruppel-like factor 2. Atherosclerosis. 2011;214(2):345-9.
91. Atkins GB, Wang Y, Mahabeleshwar GH, et al. Hemizygous deficiency of kruppel-like factor 2 augments experimental atherosclerosis. Circ Res. 2008;103(7):690-3.
92. Liao X, Sharma N, Kapadia F, et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest. 2011;121(7):2736-49.
93. Takeuch O, Akira S. Epigenetic control of macrophage polarization. Eur J Immunol. 2011;41(9):2490-3.
94. De Santa F, Totaro MG, Prosperini E, et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell. 2007;130(6):1083-94. (Pubitemid 47410272)
95. De Santa F, Narang V, Yap ZH, et al. Jmjd3 Contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 2009;28(21):3341-52.
96. Mullican SE, Gaddis CA, Alenghat T, et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 2011;25(23):2480-8.
97. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468 (7327):1119-23. This article is the first to demonstrate that pharmacologic disruption of chromatin complexes can be used to inhibit inflammatory responses.
98. Alkemade FE, van Vliet P, Henneman P, et al. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. Am J Pathol. 2010;176(2):542-8.
99. Wierda RJ, Geutskens SB, Jukema JW, et al. Epigenetics in atherosclerosis and inflammation. J Cell Mol Med. 2010;14 (6A):1225-40.
100. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8(10):802-15.